Safety analysis ofrFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from theHAVENclinical program-Reference-Cited by-同舟云学术

Safety analysis ofrFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from theHAVENclinical program

Published:2019-06-17 Issue:9 Volume:17 Page:1470-1477
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Levy Gallia G.¹,Asikanius Elina²,Kuebler Peter¹,Benchikh El Fegoun Soraya³,Esbjerg Sille⁴,Seremetis Stephanie⁵

Affiliation:

1. Genentech Inc. South San Francisco California

2. F. Hoffmann‐La Roche Ltd Basel Switzerland

3. Novo Nordisk Health Care AG Zürich Switzerland

4. Novo Nordisk A/S Søborg Denmark

5. Novo Nordisk Inc. Princeton New Jersey

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14491

Reference20 articles.

1. FDA.Highlights of prescribing information ‐ NovoSeven®RT Coagulation Factor VIIa (Recombinant). Available athttps://wwwfdagov/downloads//ucm056954pdf. 2014; Accessed 14 Sep 2018.

2. EMA.NovoSeven summary of product characteristics. Available athttp://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873pdf. 2016; Accessed 14 Sep 2018.

3. EMA.Summary of product characteristics ‐ Hemlibra. Available athttp://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004406/WC500244743pdf. 2018; Accessed 14 Sep 2018.

4. In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro‐coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC;Adamkewicz JI;Haemophilia,2017

5. Recombinant coagulation factor VIIa – from molecular to clinical aspects of a versatile haemostatic agent

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology;Journal of Thrombosis and Haemostasis;2024-09

2. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro;Thrombosis Research;2024-05

3. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

4. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

5. Emicizumab in two patients with acquired haemophilia A – case report;The Journal of Haemophilia Practice;2024-01-01